Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARECNYSE:ETXNASDAQ:SBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARECAmerican Resources$0.90+2.4%$0.69$0.38▼$1.68$69.68M1.021.77 million shs956,286 shsETXEaton Vance Municipal Income 2028 Term Trust$18.17+0.1%$18.10$17.48▼$19.44N/AN/A22,446 shs6,609 shsSBTXSilverback Therapeutics$13.35+0.5%$13.21$2.80▼$8.97$481.37M0.6337,931 shs1.44 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARECAmerican Resources+5.28%+17.51%+82.74%+40.06%-33.41%ETXEaton Vance Municipal Income 2028 Term Trust+0.14%+1.00%+2.90%+0.05%-0.54%SBTXSilverback Therapeutics-1.12%-6.80%-5.41%+15.06%+49.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARECAmerican Resources2.7469 of 5 stars3.74.00.00.02.60.80.6ETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARECAmerican Resources 3.33Buy$4.00344.44% UpsideETXEaton Vance Municipal Income 2028 Term Trust 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARECAmerican Resources$399.96K174.21N/AN/AN/A∞ETXEaton Vance Municipal Income 2028 Term Trust$6.94MN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARECAmerican Resources-$11.45M-$0.39N/A15.00N/A-8,325.31%N/A-18.58%5/20/2025 (Estimated)ETXEaton Vance Municipal Income 2028 Term TrustN/AN/A0.00∞N/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ALatest AREC, REDX, ETX, and SBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q4 2024ARECAmerican Resources-$0.05N/AN/AN/A$1.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARECAmerican ResourcesN/AN/AN/AN/AN/AETXEaton Vance Municipal Income 2028 Term Trust$0.864.73%+3.32%N/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ALatest AREC, REDX, ETX, and SBTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.2%5/15/20255/15/20255/30/20254/2/2025ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.1%4/15/20254/15/20254/30/20253/3/2025ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.1%3/14/20253/14/20253/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARECAmerican ResourcesN/A0.230.15ETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARECAmerican Resources9.32%ETXEaton Vance Municipal Income 2028 Term TrustN/ASBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipARECAmerican Resources16.80%ETXEaton Vance Municipal Income 2028 Term TrustN/ASBTXSilverback Therapeutics34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARECAmerican Resources1077.42 million64.41 millionOptionableETXEaton Vance Municipal Income 2028 Term Trust35N/AN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableAREC, REDX, ETX, and SBTX HeadlinesRecent News About These CompaniesSilverback Therapeutics (NASDAQ:SBTX) Stock Price Down 3.8% - Here's WhyMay 12 at 4:17 AM | marketbeat.comSilverback Therapeutics (NASDAQ:SBTX) Shares Down 0.7% - Here's WhyApril 20, 2025 | marketbeat.comMeet the Silverback, the Leader of the TroopOctober 17, 2024 | pbs.org10 Fun Facts About Mountain GorillasSeptember 18, 2024 | nationalgeographic.comCapstanTx secures $165 million to deliver precise in vivo cell engineeringJuly 28, 2024 | pharmaphorum.comARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comWild IslesMarch 12, 2023 | wwf.org.ukA look back at RNA Therapeutics – day oneFebruary 24, 2023 | pharmaphorum.comSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comFDA accepts ARS Pharma’s NDA for NeffyOctober 24, 2022 | thepharmaletter.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIOctober 23, 2022 | kentuckytoday.comSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisOctober 21, 2022 | finance.yahoo.comIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?October 19, 2022 | aaii.comSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNOctober 12, 2022 | bakersfield.comINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTSeptember 17, 2022 | markets.businessinsider.comSBTX Silverback Therapeutics, Inc.September 15, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAREC, REDX, ETX, and SBTX Company DescriptionsAmerican Resources NASDAQ:AREC$0.90 +0.02 (+2.39%) As of 04:00 PM EasternAmerican Resources Corporation, together with its subsidiaries, extracts, processes, transports, and sells metallurgical coal to the steel and industrial industries. It supplies raw materials; and sells coal used in pulverized coal injections. The company was founded in 2006 and is headquartered in Fishers, Indiana.Eaton Vance Municipal Income 2028 Term Trust NYSE:ETX$18.17 +0.02 (+0.11%) As of 03:24 PM EasternEaton Vance Municipal Income 2028 Term Trust is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in the fixed income markets. The fund invest in stocks of companies operating across the diversified sectors. It was previously known as Eaton Vance Municipal Income Term Trust. Eaton Vance Municipal Income 2028 Term Trust was formed on March 28, 2013 and is domiciled in the United States.Silverback Therapeutics NASDAQ:SBTX$13.35 +0.06 (+0.45%) As of 05/13/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
